Enzalutamide Granted Priority Review for Expanded Use in Prostate Cancer

The FDA is granting Priority Review for the expanded use of enzalutamide in nonmetastatic castration-resistant prostate cancer.

Source: CancerNetwork - March 21, 2018 Category: Cancer & Oncology Authors: John Schieszer Tags: Genitourinary Cancers News Prostate Cancer Source Type: news